Deciphera Pharmaceuticals Inc (DCPH)
25.46
+0.02
(+0.06%)
USD |
NASDAQ |
May 17, 16:00
25.46
0.00 (0.00%)
After-Hours: 20:00
Deciphera Pharmaceuticals Revenue (TTM): 174.91M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 174.91M |
| December 31, 2023 | 163.36M |
| September 30, 2023 | 151.41M |
| June 30, 2023 | 144.07M |
| March 31, 2023 | 138.26M |
| December 31, 2022 | 134.04M |
| September 30, 2022 | 121.89M |
| Date | Value |
|---|---|
| June 30, 2022 | 109.14M |
| March 31, 2022 | 100.22M |
| December 31, 2021 | 96.15M |
| September 30, 2021 | 91.44M |
| June 30, 2021 | 83.66M |
| March 31, 2021 | 67.18M |
| December 31, 2020 | 42.09M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
42.09M
Minimum
Dec 2020
174.91M
Maximum
Mar 2024
115.56M
Average
115.51M
Median
Revenue (TTM) Benchmarks
| Bristol-Myers Squibb Co | 45.53B |
| Dynavax Technologies Corp | 236.15M |
| Gilead Sciences Inc | 27.45B |
| Esperion Therapeutics Inc | 229.74M |
| SINTX Technologies Inc | 1.226M |